ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology biopharmaceutical enterprise focused on the discovery and development of next-generation cancer therapies. The company specializes in engineering specialized protein therapeutics designed to block CD47, a key signal used by tumor cells to evade destruction by the body's innate immune system. By enhancing macrophage-mediated phagocytosis, its pipeline aims to improve therapeutic outcomes when combined with standard antibody and chemotherapy treatments.